Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

Abstract Background To demonstrate equivalent efficacy of the proposed high-concentration (100 mg/ml), citrate-free adalimumab biosimilar CT-P17 to European Union-approved adalimumab (EU-adalimumab) in subjects with active rheumatoid arthritis (RA). Methods This randomized, double-blind phase III st...

Full description

Bibliographic Details
Main Authors: Jonathan Kay, Janusz Jaworski, Rafal Wojciechowski, Piotr Wiland, Anna Dudek, Marek Krogulec, Slawomir Jeka, Agnieszka Zielinska, Jakub Trefler, Katarzyna Bartnicka-Maslowska, Magdalena Krajewska-Wlodarczyk, Piotr A. Klimiuk, Sang Joon Lee, Yun Ju Bae, Go Eun Yang, Jae Kyoung Yoo, Daniel E. Furst, Edward Keystone
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Arthritis Research & Therapy
Subjects:
Adalimumab
Biologics
Biosimilars
Comparative effectiveness
Immunogenicity
Monoclonal antibodies
Online Access:https://doi.org/10.1186/s13075-020-02394-7

Internet

https://doi.org/10.1186/s13075-020-02394-7

Similar Items